Xerophthalmia, keratomalacia and nutritional blindness

Research output: Contribution to journalArticle

Abstract

Vitamin A deficiency remains a major cause of pediatric ocular morbidity. Over five million children develop xerophthalmia annually, a quarter million or more becoming blind. It is also a major pathway for measles-associated blindness, particularly in Africa. Treatment is practical and inexpensive, based upon the oral administration of 200,000 IU vitamin A on two successive days, at a cost of 10 cents U.S. Given the potential rapidity of corneal necrosis (keratomalacia) and the relative inaccessibility of health services to those at greatest risk, prevention is probably more important than treatment. Oral administration of high dose supplements (2000,000 IU every 3 to 6 months), vitamin A fortification of commonly consumed items, or best of all, increased dietary intake of natural sources of vitamin A will reduce the number of needlessly blind young children. Given recent evidence that vitamin A deficiency greatly increases overall mortality, even among children without evidence of xerophthalmia, the same prophylactic regimen may improve child survival by 35% or more.

Original languageEnglish (US)
Pages (from-to)195-199
Number of pages5
JournalInternational Ophthalmology
Volume14
Issue number3
DOIs
StatePublished - May 1990

Fingerprint

Xerophthalmia
Blindness
Vitamin A
Vitamin A Deficiency
Oral Administration
Measles
Health Services
Necrosis
Pediatrics
Morbidity
Costs and Cost Analysis
Mortality
Keratomalacia
Therapeutics

Keywords

  • child survival
  • keratomalacia
  • nutritional blindness
  • vitamin A deficiency
  • xerophthalmia

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Xerophthalmia, keratomalacia and nutritional blindness. / Sommer, Alfred.

In: International Ophthalmology, Vol. 14, No. 3, 05.1990, p. 195-199.

Research output: Contribution to journalArticle

@article{2694f3c4e38f4db3ac97ae6e10ea4bf1,
title = "Xerophthalmia, keratomalacia and nutritional blindness",
abstract = "Vitamin A deficiency remains a major cause of pediatric ocular morbidity. Over five million children develop xerophthalmia annually, a quarter million or more becoming blind. It is also a major pathway for measles-associated blindness, particularly in Africa. Treatment is practical and inexpensive, based upon the oral administration of 200,000 IU vitamin A on two successive days, at a cost of 10 cents U.S. Given the potential rapidity of corneal necrosis (keratomalacia) and the relative inaccessibility of health services to those at greatest risk, prevention is probably more important than treatment. Oral administration of high dose supplements (2000,000 IU every 3 to 6 months), vitamin A fortification of commonly consumed items, or best of all, increased dietary intake of natural sources of vitamin A will reduce the number of needlessly blind young children. Given recent evidence that vitamin A deficiency greatly increases overall mortality, even among children without evidence of xerophthalmia, the same prophylactic regimen may improve child survival by 35{\%} or more.",
keywords = "child survival, keratomalacia, nutritional blindness, vitamin A deficiency, xerophthalmia",
author = "Alfred Sommer",
year = "1990",
month = "5",
doi = "10.1007/BF00158318",
language = "English (US)",
volume = "14",
pages = "195--199",
journal = "International Ophthalmology",
issn = "0165-5701",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Xerophthalmia, keratomalacia and nutritional blindness

AU - Sommer, Alfred

PY - 1990/5

Y1 - 1990/5

N2 - Vitamin A deficiency remains a major cause of pediatric ocular morbidity. Over five million children develop xerophthalmia annually, a quarter million or more becoming blind. It is also a major pathway for measles-associated blindness, particularly in Africa. Treatment is practical and inexpensive, based upon the oral administration of 200,000 IU vitamin A on two successive days, at a cost of 10 cents U.S. Given the potential rapidity of corneal necrosis (keratomalacia) and the relative inaccessibility of health services to those at greatest risk, prevention is probably more important than treatment. Oral administration of high dose supplements (2000,000 IU every 3 to 6 months), vitamin A fortification of commonly consumed items, or best of all, increased dietary intake of natural sources of vitamin A will reduce the number of needlessly blind young children. Given recent evidence that vitamin A deficiency greatly increases overall mortality, even among children without evidence of xerophthalmia, the same prophylactic regimen may improve child survival by 35% or more.

AB - Vitamin A deficiency remains a major cause of pediatric ocular morbidity. Over five million children develop xerophthalmia annually, a quarter million or more becoming blind. It is also a major pathway for measles-associated blindness, particularly in Africa. Treatment is practical and inexpensive, based upon the oral administration of 200,000 IU vitamin A on two successive days, at a cost of 10 cents U.S. Given the potential rapidity of corneal necrosis (keratomalacia) and the relative inaccessibility of health services to those at greatest risk, prevention is probably more important than treatment. Oral administration of high dose supplements (2000,000 IU every 3 to 6 months), vitamin A fortification of commonly consumed items, or best of all, increased dietary intake of natural sources of vitamin A will reduce the number of needlessly blind young children. Given recent evidence that vitamin A deficiency greatly increases overall mortality, even among children without evidence of xerophthalmia, the same prophylactic regimen may improve child survival by 35% or more.

KW - child survival

KW - keratomalacia

KW - nutritional blindness

KW - vitamin A deficiency

KW - xerophthalmia

UR - http://www.scopus.com/inward/record.url?scp=0025303132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025303132&partnerID=8YFLogxK

U2 - 10.1007/BF00158318

DO - 10.1007/BF00158318

M3 - Article

C2 - 2188921

AN - SCOPUS:0025303132

VL - 14

SP - 195

EP - 199

JO - International Ophthalmology

JF - International Ophthalmology

SN - 0165-5701

IS - 3

ER -